Guideline
Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Michel Perreault and Christy Sutherland
CMAJ September 23, 2019 191 (38) E1049-E1056; DOI: https://doi.org/10.1503/cmaj.190344
Nadia Fairbairn
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDJosey Ross
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MAMichael Trew
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDKarine Meador
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDJeff Turnbull
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDScott MacDonald
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDEugenia Oviedo-Joekes
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
PhDBernard Le Foll
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDMarie-Ève Goyer
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MDMichel Perreault
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
PhDChristy Sutherland
Department of Medicine (Fairbairn, Sutherland), University of British Columbia; British Columbia Centre on Substance Use (Fairbairn, Ross, Sutherland), Vancouver, BC; Department of Psychiatry, Faculty of Medicine (Trew), University of Calgary; Alberta Health Services (Trew), Calgary, Alta.; Inner City Health and Wellness Program and Addiction Recovery and Community Health (Meador), Royal Alexandra Hospital, Edmonton, Alta.; Ottawa Inner City Health (Turnbull), Ottawa, Ont.; Providence Crosstown Clinic (MacDonald); School of Population and Public Health (Oviedo-Joekes), University of British Columbia; Centre for Health Evaluation & Outcome Sciences (Oviedo-Joekes), Providence Health Care, Vancouver, BC; Translational Addiction Research Laboratory (Le Foll), Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry (Le Foll), Institute of Medical Science, University of Toronto, Toronto, Ont.; Département de médicine de famille et de médicine d’urgence (Goyer), Faculté de médicine, Université de Montréal; Centre de recherche et d’aide pour narcomanes (Goyer), Centre intégré universitaire de santé et de services sociaux du Centre-Sudde-I’Île-de-Montréal; Department of Psychiatry (Perreault), McGill University; Douglas Mental Health Institute (Perreault), Montréal, Que.; PHS Community Services Society (Sutherland), Vancouver, BC
MD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article extras
Podcast
Article tools
Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Michel Perreault, Christy Sutherland
CMAJ Sep 2019, 191 (38) E1049-E1056; DOI: 10.1503/cmaj.190344
Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Michel Perreault, Christy Sutherland
CMAJ Sep 2019, 191 (38) E1049-E1056; DOI: 10.1503/cmaj.190344
Jump to section
Related Articles
Cited By...
- Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario
- Lignes directrices de pratique clinique pour les personnes sans-abri, logees precairement, ou ayant connu litinerance
- Harm Reduction Services in Ottawa: The Culture of Drug Use
- Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience
- Problems with hydromorphone prescribing as a response to the opioid crisis